Several phenotypic, molecular and chromosomal markers of chronic lymphocytic leukemia (CLL) cells have been identified that are significantly associated with patient prognosis.1, 2, 3, 4, 5, 6 However, these markers used singularly are inaccurate predictors of outcome for individual patients. Recent efforts have focused on combining markers to predict either treatment-free survival (TFS)4, 7, 8 or overall survival (OS),9, 10, 11 however, further effort is worthwhile to determine how to combine prognostic parameters, optimize risk stratification, simplify calculations and/or identify new prognostic variables.

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients / Gentile, M; Shanafelt, Td; Cutrona, G; Molica, S; Tripepi, G; Alvarez, I; Mauro, F. R; Di Renzo, N; Di Raimondo, F; Vincelli, I; Todoerti, K; Matis, S; Musolino, C; Fabris, S; Vigna, E; Levato, L; Zupo, S; Angrilli, F; Consoli, U; Festini, G; Longo, G; Cortelezzi, A; Arcari, A; Federico, Massimo; Mannina, D; Recchia, Ag; Neri, A; Kay, Ne; Ferrarini, M; Morabito, F.. - In: LEUKEMIA. - ISSN 0887-6924. - 30:(2016), pp. 1440-1443. [10.1038/leu.2015.333]

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

FEDERICO, Massimo;
2016

Abstract

Several phenotypic, molecular and chromosomal markers of chronic lymphocytic leukemia (CLL) cells have been identified that are significantly associated with patient prognosis.1, 2, 3, 4, 5, 6 However, these markers used singularly are inaccurate predictors of outcome for individual patients. Recent efforts have focused on combining markers to predict either treatment-free survival (TFS)4, 7, 8 or overall survival (OS),9, 10, 11 however, further effort is worthwhile to determine how to combine prognostic parameters, optimize risk stratification, simplify calculations and/or identify new prognostic variables.
2016
9-dic-2015
30
1440
1443
A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients / Gentile, M; Shanafelt, Td; Cutrona, G; Molica, S; Tripepi, G; Alvarez, I; Mauro, F. R; Di Renzo, N; Di Raimondo, F; Vincelli, I; Todoerti, K; Matis, S; Musolino, C; Fabris, S; Vigna, E; Levato, L; Zupo, S; Angrilli, F; Consoli, U; Festini, G; Longo, G; Cortelezzi, A; Arcari, A; Federico, Massimo; Mannina, D; Recchia, Ag; Neri, A; Kay, Ne; Ferrarini, M; Morabito, F.. - In: LEUKEMIA. - ISSN 0887-6924. - 30:(2016), pp. 1440-1443. [10.1038/leu.2015.333]
Gentile, M; Shanafelt, Td; Cutrona, G; Molica, S; Tripepi, G; Alvarez, I; Mauro, F. R; Di Renzo, N; Di Raimondo, F; Vincelli, I; Todoerti, K; Matis, S; Musolino, C; Fabris, S; Vigna, E; Levato, L; Zupo, S; Angrilli, F; Consoli, U; Festini, G; Longo, G; Cortelezzi, A; Arcari, A; Federico, Massimo; Mannina, D; Recchia, Ag; Neri, A; Kay, Ne; Ferrarini, M; Morabito, F.
File in questo prodotto:
File Dimensione Formato  
424.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 447.37 kB
Formato Adobe PDF
447.37 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1105307
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
social impact